ArticleScientific reports2025
Investigating the role of Rubus coreanus in enhancing peri-implant bone healing in healthy and estrogen-deficient rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Osseointegration can be compromised by bone diseases such as osteoporosis, negatively affecting the quality of life in affected individuals. Rubus coreanus (RC) has shown potential in modulating bone metabolism. Thus, this study aimed to evaluate the impact of RC-functionalized implants on peri-implant bone healing in both healthy (SHAM) and ovariectomized (OVX) rats. The research included both in vitro and in vivo experiments. Initially, osteoblastic cell cultures were used to assess the response to functionalized discs, followed by an in vivo study with forty-eight female Wistar rats, randomly assigned to six groups: SHAM CONV, SHAM RC 200, SHAM RC 400, OVX CONV, OVX RC 200, and OVX RC 400, where CONV refers to a conventional titanium implant and 200 and 400 represent that implant coated with 200 µg and 400 µg of RC. SHAM groups underwent fictitious surgery, while OVX groups underwent ovariectomy. After 30 days, implants were placed in the tibial metaphysis, and the rats were euthanized at 28 days post-implantation. Results indicated that RC maintained cell viability without significantly altering bone microarchitecture. Immunohistochemical analysis revealed notable histological improvements and enhanced marker expression, particularly with the RC 200 surface. Ultrastructural analysis suggested that RC functionalization improves peri-implant bone healing, especially in healthy rats treated with RC 200. In conclusion, implant functionalization with RC, particularly RC 200 significantly enhances peri-implant bone healing, with the most pronounced effects observed in SHAM group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.